A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

MLA

Cooper, Todd M., et al. “A Phase 1 Study of the CXCR4 Antagonist Plerixafor in Combination with High-Dose Cytarabine and Etoposide in Children with Relapsed or Refractory Acute Leukemias or Myelodysplastic Syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium Study (POE 10-03).” Pediatric Blood & Cancer, vol. 64, no. 8, Aug. 2017. EBSCOhost, https://doi.org/10.1002/pbc.26414.

APA

Cooper, T. M., Sison, E. A. R., Baker, S. D., Li, L., Ahmed, A., Trippett, T., Gore, L., Macy, M. E., Narendran, A., August, K., Absalon, M. J., Boklan, J., Pollard, J., Magoon, D., & Brown, P. A. (2017). A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10-03). Pediatric Blood & Cancer, 64(8). https://doi.org/10.1002/pbc.26414

Chicago

Cooper, Todd M, Edward Allan Racela Sison, Sharyn D Baker, Lie Li, Amina Ahmed, Tanya Trippett, Lia Gore, et al. 2017. “A Phase 1 Study of the CXCR4 Antagonist Plerixafor in Combination with High-Dose Cytarabine and Etoposide in Children with Relapsed or Refractory Acute Leukemias or Myelodysplastic Syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium Study (POE 10-03).” Pediatric Blood & Cancer 64 (8). doi:10.1002/pbc.26414.